Conference abstract · 27 Jun 2019
Conference abstractPublished 20 Sep 2019
Endogenous Insulin Secretion should be priority in Type-2 Therapy
Jeeva Therapeutics, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
It is argued - why the preferred method to maintain euglycemia in type-2 should be prioritizing the endogenous insulin secretion, while suggesting possible approaches to research further in that direction. It is known, that most types of peripherally administered insulin (PAI) have drawbacks; viz. being non-native, lacking c-peptide, not mimicking physiological insulin secretion oscillations (ISO) that reduce insulin receptor saturation, contributing to weight gain (often as visceral fat). Also, PAI is far less effective in countering gluconeogenesis, a contributor to hyperglycemia, as it doesn’t mimic pancreatic release of insulin into the hepatic entrance of the portal vein as triggered by feeding. Merely maintaining tight-glycemic control may not necessarily reduce endothelial dysfunction. Hence, it may be more beneficial to steer away from PAI as well as exogenous insulin. Although, recent research demonstrates the merits of portally administered insulin, access to the portal vein is not practical. Clearly, stem cells are the right approach and deserve high priority. While DPP4-I/GLP-1, even with concomitant Glitazones, is good therapeutic approaches, they remain insufficient to achieve tight glycemic control. They, also, fail to mimic the ISO and feeding correlated hepatic portal secretion. Meanwhile it may be beneficial to revisit insulin secretagogues (IS) and modify traditional therapy, while improving approaches to endogenous secretion and concomitantly minimizing side effects. Dosage of sulfonylureas should be reduced to maintain a very basal secretion. This should be co-administered with a short acting IS (e.g. meglitinides) prior to feeding. This approach can be titrated to mimic native secretion. Effort should be made to find new molecules that enhance secretion efficiency while minimizing side effects. While β-cell ion channels have been exploited, more effort is needed to exploit the glycolysis/glucokinase aspect
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2014
Combination therapy to preserve residual insulin secretion in type 1 diabetes
Conference abstract · 2 Nov 2017
Bio-fabrication and evaluation of alginate chitosan microcapsules of insulin secreting TC-6 cells in the treatment of type 1 diabetes mellitus
Conference abstract · 2 Nov 2017
Bio-fabrication and evaluation of alginate chitosan microcapsules of Insulin secreting β TC-6 cells in the treatment of Type 1 diabetes mellitus
Conference proceeding · 2022
Role of pulsed endogenous insulin in type-2 diabetes therapy
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Ravikumar Muppirala”
